Morphinan Derivatives Targeting NMDA Receptors for Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, such as sulfonylureas and DPP-4 inhibitors, are inadequate as they often lead to hypoglycemia and do not effectively slow the progression of beta-cell destruction in type 2 diabetes, while existing oral antidiabetic drugs like metformin have limitations in long-term efficacy and safety.
Innovation Solution
Development of morphinan-derivatives with dextrorotatory (+) stereochemistry that target NMDA receptors on pancreatic islets, specifically increasing insulin secretion only at elevated glucose levels, thereby avoiding hypoglycemia and potentially slowing the progression of type 2 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If sulfonylureas are administered to decrease glucose levels, then glucose control is improved, but the risk of hypoglycemia increases
Solution Approach 1:
The patent applies parameter changes by developing morphinan derivatives with specific dextrorotatory stereochemistry that modulate the insulin secretion response curve. The compound shifts the glucose concentration range for insulin secretion upward, making secretion occur only at higher glucose levels rather than at normal physiological ranges, thereby avoiding hypoglycemia while maintaining glucose control efficacy
Solution Approach 2:
The morphinan derivative acts as an intermediary substance that mediates between glucose and insulin secretion. It binds to specific receptors on pancreatic beta cells and transduces the glucose signal into an insulin secretion response, but only when glucose levels are elevated, thus providing a buffered, controlled response that prevents excessive insulin release and subsequent hypoglycemia
2Reliability
If metformin is used for long-term treatment, then diabetes complications are reduced, but efficacy deteriorates over time due to beta cell function decline
Solution Approach 1:
The morphinan derivative enables self-service by directly stimulating pancreatic beta cells to maintain their secretory function. The compound activates specific receptors on beta cells that promote their ability to respond to glucose and secrete insulin, allowing the beta cells to sustain their function autonomously without relying solely on external insulin administration or metabolic adaptation to declining beta cell mass
3Object-affected harmful factors
If DDP-4 inhibitors are administered, then hypoglycemia risk is reduced, but HbA1c improvement is only slight
Solution Approach 1:
The patent applies dynamics by creating a glucose-responsive insulin secretion system. The morphinan derivative dynamically adjusts insulin secretion based on real-time glucose levels, increasing secretion only when glucose is elevated and reducing it when glucose normalizes, thereby achieving both hypoglycemia avoidance and meaningful HbA1c reduction through adaptive, context-dependent insulin release
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) wherein R1 is selected from -OH, -CO2H, -R0, -OR0, -OC(=O)R0, -OC(=O)OR0 or -OC(=O)NHR0; and R2 is selected from -H, -R0, -C(=O)R0, -C(=O)OR0, -C(=O)NHR0 or -C(=NH)-NH- C(=NH)-NH2; wherein R0 is in each case independently selected from -C1-C6-alkyl, - aryl, -heteroaryl, -C1-C6-alkyl-aryl or -C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and/or diabetic nephropathy.